Appointment dossier — Prostate Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Genistein — Review evidence · 1 positive · PMID 42133114
- Relacorilant — Review evidence · 1 positive · PMID 42334771
- Carboplatin — Review evidence · 0 positive · PMID 37485216
- Durvalumab — Review evidence · 0 positive · PMID 37485216
- Etoposide — Review evidence · 0 positive · PMID 37485216
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07500701 · Phase 3 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer (South Korea)
- NCT06592924 · Phase 3 — Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (United States)
- NCT05381103 · Phase 2 / Phase 3 — PSMA-PET to Guide Prostatectomy (United States)
- NCT06067269 · Phase 2 — Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (United States)
- NCT07247175 · Phase 2 — The Impact of Force Feedback in the dV5 Robotic Surgical System on Learning Curve and Safety in Robot-Assisted Radical Prostatectomy - A Prospective, Single-Center, Investigator-Initiated Clinical Trial (South Korea)
- NCT07001241 · Phase 2 — Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors (United States)
- NCT06259123 · Phase 2 — Neoadjuvant PSMA-RLT in Oligometastatic PCa (Austria)
- NCT06922318 · Phase 2 — The COSMYC Trial (COmbined Suppression of MYC) (United States)
- NCT07237269 · Phase 2 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer (United States)
- NCT06636682 · Phase 2 — FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer (United States)
- NCT05563558 · Phase 2 — Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) (Spain)
- NCT06369246 · Phase 1 — PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. (United States)
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer (United States)
- NCT06482645 — Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer (China)
- NCT07463092 — Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (Brazil)
- NCT06468332 — Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer (Italy)
- NCT06652607 — PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer (Italy)
- NCT02869594 — Institut Paoli Calmettes Prostate Cancer Database (France)
Most-relevant first: trials that name Prostate Cancer, then broader trials you may still qualify for. 1216 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07500701), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?